Omeros (OMER) Cash from Financing Activities (2010 - 2026)
Omeros (OMER) reported Cash from Financing Activities of -$22.0 million for Q1 2026, down 1095.32% on a YoY basis from $2.2 million in Q1 2025, and up 65.89% sequentially from -$64.4 million in Q4 2025.
Omeros (OMER) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Omeros (OMER) has 17 years of Cash from Financing Activities data on file, last reported at -$22.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 1095.32% year-over-year to -$22.0 million; the trailing twelve-month figure through Mar 2026 stood at -$62.3 million (down 66.66% YoY), and the FY2025 full-year result was -$42.2 million, down 167.06% from the prior year.
- Cash from Financing Activities advanced to -$22.0 million in Q1 2026, from -$64.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $124.8 million in Q3 2022 to a low of -$105.0 million in Q4 2023.
- A 5-year average of $993764.7 and a median of -$651000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities jumped 26016.53% in 2022 and plunged 16021.81% in 2023, its largest moves.
- Tracing OMER's Cash from Financing Activities over 5 years: stood at -$651000.0 in 2022, then sank by 16021.81% to -$105.0 million in 2023, then soared by 96.1% to -$4.1 million in 2024, then plunged by 1473.6% to -$64.4 million in 2025, then soared by 65.89% to -$22.0 million in 2026.
- Business Quant data shows OMER's Cash from Financing Activities at -$22.0 million in Q1 2026, -$64.4 million in Q4 2025, and $25.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Omeros | 739.31 Mn | 739.31 Mn | 9.31 Mn | -21.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.98 Mn |
| Mar 31, 2026 | -21.98 Mn |
| Dec 31, 2025 | -64.44 Mn |
| Dec 31, 2025 | -64.44 Mn |
| Sep 30, 2025 | 25.83 Mn |
| Sep 30, 2025 | 25.83 Mn |
| Jun 30, 2025 | -1.72 Mn |
| Jun 30, 2025 | -1.72 Mn |
| Mar 31, 2025 | -1.84 Mn |
| Mar 31, 2025 | -1.84 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Sep 30, 2024 | -4.58 Mn |
| Sep 30, 2024 | -4.58 Mn |
| Jun 30, 2024 | -26.88 Mn |
| Jun 30, 2024 | -26.88 Mn |
| Mar 31, 2024 | 98.43 Mn |
| Mar 31, 2024 | 98.43 Mn |
| Dec 31, 2023 | -104.95 Mn |
| Dec 31, 2023 | -104.95 Mn |